RESEARCH USING PATIENTS WHO FIT THE INTERNATIONAL CONSENSUS CRITERIA*
Please share this page to your favorite social media sites!
2021
Skewing of the B cell receptor repertoire in ME/CFS Sato, Ono, Matsutani, Nakamura, Shin, Amano, Suzuki & Yamamura (Japan) - ICC, CCC and Fukuda - Conclusion: "... we revealed a biased usage of several IGHV genes in peripheral blood B cells from ME/CFS patients. Results of receiver operating characteristic (ROC) analysis further indicated a possibility of distinguishing patients from healthy controls, based on the skewed B cell repertoire." - 27 March 21
Open-label study with the monoamine stabilizer (-)-OSU6162 in ME/CFS Haghighi, Forsmark, Zachrisson, Carlsson, Nilsson, Carlsson, Schuit & Gottfries (Sweden & The Netherlands) - ICC and Fukuda - Conclusion: "(‐)‐OSU6162 is well tolerated in ME/CFS patients and shows promise as a novel treatment to mitigate fatigue and improve mood and health‐related quality of life in ME/CFS. Obviously, the present results need to be confirmed in future placebo‐controlled double‐blind trials." - 02 February 21
2020
Deep phenotyping of myalgic encephalomyelitis/chronic fatigue syndrome in Japanese population Kitami, Fukuda, Kato, Yamaguti, Nakatomi, Yamano, Kataoka, Mizuno, Tsuboi, Kogo, Suzuki, Itoh, Morioka, Kawaji, Koseki, Kikuchi, Hayashizaki, Ohno, Kuratsune & Watanabe (Japan) - ICC and Fukuda - Conclusion: "Our study points to a cluster of sleep-related molecular changes as a prominent feature of ME/CFS in our Japanese cohort." - 16 November 20
The Economic Impacts of ME/CFS in an Australian Cohort Close, Marshall-Gradisnik, Byrnes, Smith, Nghiem and Stains (Australia) - Conclusion: The economic impacts of ME/CFS in Australia are significant. Improved understanding of the illness pathology, diagnosis, and management, may reduce costs, improve patient prognosis and decrease the burden of ME/CFS in Australia. - 21 August 20
Review of case definitions for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Lim and Son (Republic of Korea) - "...ME/CFS has been named differently (e.g., postviral fatigue syndrome, neurasthenia) depending on the perspectives of the researchers; likewise, diagnostic criteria or case definitions have also been changed accordingly." Conclusions: "In this review, we found three key factors that have affected ME/CFS case definitions: etiology, pathophysiology, and exclusionary disorders. These factors have impacted the specification of the main symptoms, required conditions, and range of inclusive and exclusive symptoms/disorders in the development of case definitions." - 29 July 20
Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with CFS Loebel, Grabowski, Heidecke, Bauer, Hanitsch, Wittke, Meisel, Reinke, Volk, Fluge, Mella and Scheibenbogen (Germany & Norway) Results: "We found significantly higher autoantibody levels against M3 and M4 AChR and β2 AdR in CFS patients compared to controls. Crossreactivity between all 5 M and β1 and β2 AdR but also between M and β receptor was seen in a substantial portion of CFS patients as shown for M4 in Fig. 1C. The highest correlation was found between M3 and M4 receptor antibodies (r = 0.87), the lowest for M1 and M4 receptor antibodies (r = 0.59)." - 19 Sept 15
Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in ME/CFS Patient selection - CCC Schreiner, Harrer, Scheibenbogen, Lamer, Schlosser, Naviaux and Prusty (Germany/US) - 01 April 20
Note: Some studies use various labels (ME/CFS, CFS, CFS/ME) due to the inconsistent use of these labels worldwide. This list focuses on the research subjects used showing research is applicable to myalgic encephalomyelitis.